9th Annual Heart in Diabetes (HiD) CME Conference

9th Annual Heart in Diabetes (HiD) CME Conference is organized by The Metabolic Institute of America (TMIOA), Metabolic Endocrine Education Foundation (MEEF) and will be held from Jun 06 - 08, 2025 at Loews Philadelphia Hotel, Philadelphia, Pennsylvania, United States of America.

Program Description:
The Heart in Diabetes (HiD) brings a multi-specialty world-renowned leaders in diabetes, obesity, and cardiorenal metabolic diseases interpreting state of the art clinical data to improve the care of the complex patients with these comorbidities.  

This year, the conference will focus on incorporating emerging data including clinical trials outcome into clinical practice.  Emphasis will be given on implementing Guidelines Directed Medical Treatment, addressing when and how to intervene early- to prevent and manage morbidities in patients with Diabetes, cardiorenal and metabolic diseases. The program will mix didactic presentations with cross-specialty panels with leading experts in cardiology, nephrology, endocrinology, and primary care experts. The interactive discussions allows ample time for Q & A , addressing treatment modalities, and implications to practice providing tools to ultimately improve the outcome of these patients.

The meeting will cover a wide range of topics including Obesity and Diabetes impact on Heart and Kidney, Women's Health, ASCVD, HF, Roles of Digital & Technology, Cardiomyopathy, Stroke Prevention and Treatment, Diabetes Management, Lipid Disorders, and emerging unique topics in the Cardio-Renal-Metabolic Space.

Learning Objectives:
Upon completion of this meeting, participants should be able to:

• Evaluate the extent of vascular disease in diabetes, obesity, and cardiometabolic syndrome.
• Be able to assess cardiovascular risk in diabetes.
• Describe the different etiologies of cardiomyopathies.
• Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia as well as hyperglycemia.
• Describe optimal use of technology—specifically CGM—and digital technology and their impact on diabetes and CVD
• Be able to recognize and manage hypoglycemia and its impact on comorbidities
• Evaluate stroke in diabetes and cardiorenal metabolic disease
• Be able to evaluate prevent and manage atherosclerosis and ASCVD
• Recognize the full spectrum of Heart Failure dictating approach to management
• Know GDMT in the 4 Pillar management of HFrEF
• Develop contemporary management of HFpEF
• Discuss the impact of obesity and diets on fatty liver, CKD, CVD, and HF
• Evaluate the evidence supporting the use of GLP1-RAs, SGLT inhibitors, nonsteroidal MRAs, and other treatments to reduce CKD, HF, and cardiovascular disease and mortality in patients with T2D
• Describe new and evolving agents in dyslipidemia treatment and how they can be used to reduce ASCVD
• Explain the important role of Lp(a) in the development atherosclerosis
• Understand the potential role and impact of AHA Presidential Advisory on Cardio-Kidney-Metabolic Health
• Discuss the changes in diagnosis and management based on DCRM 2.0 Global Multispecialty Practice Recommendations
• Evaluate the impact on clinical practice of new CVOTs, including those evaluating antihyperglycemic, lipid-lowering, and other medications such as nonsteroidal MRAs and anticoagulation therapies
• Understand the role of GLP1-RAs in prevention of CVD, strokes, and CKD in diabetes and obesity
• Describe the state of heart disease in women
• Discuss diabetes, CKD, CVD, and HF in diverse populations
• Develop treatment plans to prevent and manage CKD and its complications with ACE/ARB, SGLT inhibitors, finerenone, and GLP1-RAs in combination.